Navigation Links
Profound Medical Receives IDE Approval from FDA to Conduct TULSA Clinical Trial for New Treatment for Localized Prostate Cancer
Date:9/17/2013

Toronto, Ontario (PRWEB) September 17, 2013

Profound Medical Inc. today announced that the US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to the company to conduct a clinical study of its device for the treatment of localized prostate cancer. The company is now proceeding with U.S. institutional review board submissions and anticipates initiating patient enrollment later this year.

"This is another exciting milestone for Profound Medical and we look forward to initiating our U.S. clinical trial in the coming months. The TULSA trial is a key step in validating a new, alternative therapy for treating localized prostate cancer that minimizes the risks commonly associated with treatment," states Steven Plymale, CEO at Profound Medical.

The Profound device presents the potential for significantly improved clinical outcomes and represents a marked departure from current methods by virtue of its ability to treat the whole gland in one session, with unprecedented accuracy and minimal side effects. "The objective of the TULSA trial is to demonstrate that effective elimination of cancerous tissue can be achieved safely, precisely and with significantly less risk to bladder, bowel, and erectile functions," comments Plymale.

Combining the use of thermal ultrasound therapy with real-time MR Image guidance, the Profound system operates safely within an MRI suite, offering unparalleled accuracy, using a minimally invasive, trans-urethral approach. Performed as a single session outpatient procedure, the Profound treatment affords the patient the ability to return home after a short recovery period.

Leveraging years of research and development, initiated in collaboration with the Sunnybrook Research Institute, Profound Medical’s technology is currently at clinical-ready stage. The device can function across multiple MRI platforms from various vendors and can be moved independently from scanner to scanner. Profound Medical’s TULSA trial will effectively collect clinical data in multiple jurisdictions concurrently, accelerating the company’s commercialization plans. "We believe the TULSA clinical trial will radically change the perception of localized prostate cancer treatment, raising the bar for improved efficacy, faster recovery, and better long-term quality of life" concludes Plymale.

About Profound Medical Inc

PMI is a Canadian medical device company that is developing and commercializing a unique, minimally invasive treatment for prostate cancer. PMI’s novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. Delivered via a trans-urethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. This method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The potential of this technology is currently being demonstrated in Phase I clinical trials.

For more information, please contact:

Steven Plymale Tel: +1 647 476 1350 ext. 401 Fax: +1 647 847 3739

Read the full story at http://www.prweb.com/releases/prostate/cancer/prweb11125102.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
2. DiaTech Life Sciences Announces Medical Advisory Board
3. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
6. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
7. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
8. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
9. Live Press Briefing on Findings of Biomedical Industry CEO Survey
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Pittcon 2016 Exposition, which ... will include 848 exhibitors (count as of February 9) of which 119 are ... used by the scientific community in industrial, academic, and government labs. The Exposition ...
(Date:2/12/2016)... FRANCISCO , February 12, 2016 ... Medicine Efforts by Enabling Scientific Understanding of Complex ... and Rare Diseases --> ... genomic diagnostics in South Asia and a leading provider ... would contribute $10 million to the GenomeAsia 100K ...
(Date:2/11/2016)... 2016  Vermillion, Inc. (NASDAQ: VRML ), a ... the formation of the Steering Committee for its Pelvic ... --> Pelvic masses can present physicians and healthcare ... pregnancy is ruled out, pelvic masses may include cancers ... benign ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):